ALNY - Why Newly Listed Korro Bio Shares Are Gaining Today | Benzinga
H.C. Wainwright initiated coverage on Korro Bio Inc (NASDAQ: KRRO), a biotech company developing genetic medicines focused on editing ribonucleic acid (RNA) to treat various diseases.
Recently, Korro Bio went public via a reverse merger with Frequency Therapeutics Inc. in an all-stock merger transaction.
Approximately $170 million post-transaction cash is expected to fund operations into 2026.
The analysts Mitchell S. Kapoor and Raghuram ...